Jeffrey E. Madonna

Array ( [id] => 18726269 [patent_doc_number] => 20230340537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => SMALL TYPE II-D CAS PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/793115 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 170570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18726269 [patent_doc_number] => 20230340537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => SMALL TYPE II-D CAS PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/793115 [patent_app_country] => US [patent_app_date] => 2021-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 170570 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16914031 [patent_doc_number] => 20210187123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => ENHANCED CARDIOMYOCYTE REGENERATION [patent_app_type] => utility [patent_app_number] => 17/115698 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10823 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17115698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883729 [patent_doc_number] => 20210169924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => PREVENTION AND TREATMENT OF OCULAR INFECTION, COMPOSITION AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 17/108060 [patent_app_country] => US [patent_app_date] => 2020-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 4 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17108060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883729 [patent_doc_number] => 20210169924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => PREVENTION AND TREATMENT OF OCULAR INFECTION, COMPOSITION AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 17/108060 [patent_app_country] => US [patent_app_date] => 2020-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17110 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 4 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17108060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824641 [patent_doc_number] => 20210139934 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => TRANSGENE CASSETTES, AAV VECTORS AND AAV VIRAL VECTORS FOR THE EXPRESSION OF HUMAN CODON-OPTIMIZED SLC6A1 [patent_app_type] => utility [patent_app_number] => 17/092240 [patent_app_country] => US [patent_app_date] => 2020-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17092240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414320 [patent_doc_number] => 20220049224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => CULTURE MODIFICATIONS OF STEM CELLS TO ENHANCE THERAPEUTIC RECOVERY FROM TISSUE DAMAGE AND ISCHEMIA-REPERFUSION INJURY AND DELAYED ORGAN FUNCTION [patent_app_type] => utility [patent_app_number] => 17/086315 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17086315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16793245 [patent_doc_number] => 20210123062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => ANTI-FIBROTIC COMPOSITIONS COMPRISING FENDRR OR FRAGMENTS OR VARIANTS THEREOF AND METHODS OF PRODUCTION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/082617 [patent_app_country] => US [patent_app_date] => 2020-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17082617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839861 [patent_doc_number] => 20210147873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/077682 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17077682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17311886 [patent_doc_number] => 20210400934 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => HETEROZYGOUS TRANSGENIC ANIMAL [patent_app_type] => utility [patent_app_number] => 17/072591 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762649 [patent_doc_number] => 20210108230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => CARBOXYLATED NANODIAMOND-MEDIATED CRISPR-CAS9 DELIVERY SYSTEM [patent_app_type] => utility [patent_app_number] => 17/071667 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552442 [patent_doc_number] => 20230250451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => APPLICATION OF METHIONINASE GENE THERAPY IN TREATMENT OF MALIGNANT TUMOR [patent_app_type] => utility [patent_app_number] => 18/012877 [patent_app_country] => US [patent_app_date] => 2020-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3789 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17112186 [patent_doc_number] => 20210292783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => CHO CELL LINE, CONSTRUCTION THEREOF AND RECOMBINANT PROTEIN EXPRESSION SYSTEM USING CHO CELL LINE [patent_app_type] => utility [patent_app_number] => 16/937439 [patent_app_country] => US [patent_app_date] => 2020-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4581 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16937439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16513229 [patent_doc_number] => 20200392487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => EXCISION OF RETROVIRAL NUCLEIC ACID SEQUENCES [patent_app_type] => utility [patent_app_number] => 16/926427 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16926427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17898382 [patent_doc_number] => 20220308044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => NOVEL LIVE-CELL ASSAY FOR NEURONAL ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/616111 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17898382 [patent_doc_number] => 20220308044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => NOVEL LIVE-CELL ASSAY FOR NEURONAL ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/616111 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748298 [patent_doc_number] => 20220226501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => Insulin gene therapy [patent_app_type] => utility [patent_app_number] => 17/614390 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640630 [patent_doc_number] => 20220168368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => RECOMBINANT ONCOLYTIC VIRUS, PREPARATION METHOD THEREFOR, USE THEREOF AND MEDICINE THEREOF [patent_app_type] => utility [patent_app_number] => 17/614970 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776931 [patent_doc_number] => 20220243280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => NTRK FUSION MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/613818 [patent_app_country] => US [patent_app_date] => 2020-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 164961 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -93 [patent_words_short_claim] => 676 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613818 [rel_patent_id] =>[rel_patent_doc_number] =>)